NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus

Sharon A. Swanger, Emory University
Katie M. Vance, Emory University
Jean-François Pare, Emory University
Florence Sotty, Division of Neurodegeneration and Biologics, Denmark
Karina Fog, Division of Neurodegeneration and Biologics, Denmark
Yoland Smith, Emory University
Stephen Traynelis, Emory University

Journal Title: Journal of Neuroscience Nursing
Volume: Volume 35, Number 48
Publisher: Lippincott, Williams & Wilkins | 2015-12-02, Pages 15971-15983
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1523/JNEUROSCI.1702-15.2015
Permanent URL: https://pid.emory.edu/ark:/25593/rn811

Final published version: http://dx.doi.org/10.1523/JNEUROSCI.1702-15.2015

Copyright information:
©2015 the authors.

Accessed April 23, 2019 9:35 PM EDT
**NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus**

Sharon A. Swanger, Katie M. Vance, Jean-François Pare, Florence Sotty, Karina Fog, Yoland Smith, and Stephen F. Traynelis

1Department of Pharmacology and 2Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, 3Yerkes National Primate Research Center and Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Emory University, Atlanta, Georgia 30329, and 4H. Lundbeck A/S, Division of Neurodegeneration and Biologics, Ottiliavej 9, DK-2500 Valby, Denmark

The GluN2D subunit of the NMDA receptor is prominently expressed in the basal ganglia and associated brainstem nuclei, including the subthalamic nucleus (STN), globus pallidus, striatum, and substantia nigra. However, little is known about how GluN2D-containing NMDA receptors contribute to synaptic activity in these regions. Using Western blotting of STN tissue punches, we demonstrated that GluN2D is expressed in the rat STN throughout development [age postnatal day 7 (P7)–P60] and in the adult (age P120). Immunoelectron microscopy of the adult rat brain showed that GluN2D is predominantly expressed in dendrites, unmyelinated axons, and axon terminals within the STN. Using subunit-selective allosteric modulators of NMDA receptors (TCN-201, ifenprodil, CIQ, and DQP-1105), we provide evidence that receptors containing the GluN2B and GluN2D subunits mediate responses to exogenously applied NMDA and glycine, as well as synaptic NMDA receptor activation in the STN of rat brain slices. EPSCs in the STN were mediated primarily by AMPA and NMDA receptors and GluN2D-containing NMDA receptors controlled the slow deactivation time course of EPSCs in the STN. In vivo recordings from the STN of anesthetized adult rats demonstrated that the spike firing rate was increased by the GluN2C/D potentiator CIQ and decreased by the GluN2C/D antagonist DQP-1105, suggesting that NMDA receptor activity can influence STN output. These data indicate that the GluN2B and GluN2D NMDA receptor subunits contribute to synaptic activity in the STN and may represent potential therapeutic targets for modulating subthalamic neuron activity in neurological disorders such as Parkinson’s disease.

**Key words:** excitatory synapse; GluN2B; GluN2D; glutamate receptor; NMDA; subthalamic nucleus

---

**Introduction**

The subthalamic nucleus (STN) is a key component of the basal ganglia, a group of subcortical nuclei that control movement and are dysregulated in movement disorders such as Parkinson’s disease. Subthalamic neurons receive direct excitatory input, but the pharmacology of excitatory synaptic transmission in the STN has been understudied. Here, we show that GluN2B- and GluN2D-containing NMDA receptors mediate the NMDA receptor component of EPSCs in subthalamic neurons. Moreover, our results demonstrate that pharmacologic modulation of GluN2D-containing receptors alters the time course of EPSCs and controls the in vivo spike-firing rate in the STN. This study identifies GluN2D as a potential target for modulating subthalamic neuron activity.
regulated by several types of afferents, including excitatory inputs from the cortex, thalamus, pedunculopontine nucleus, and superior colliculus (Ashpöur, 1985; Canetras et al., 1988; Féger et al., 1994; Nambu et al., 1996; Féger, 1997). STN neurons also receive inhibitory inputs from the globus pallidus external (Smith and Grace, 1992; Shink et al., 1996; Bolam et al., 2002; Karachi et al., 2005) and dopaminergic inputs from the substantia nigra pars compacta (SNc) (Hassani et al., 1997; Prensa et al., 2000; Cragg et al., 2004). The loss of SNc neurons in Parkinson’s disease leads to altered firing patterns in the STN, which correlates with the development of motor symptoms in patients and in animal models of the disease (Hamani et al., 2004; Wilson and Bevan, 2011). In addition, synchronous firing between the STN and motor cortex increases in the disease state, suggesting that activity at glutamatergic cortical inputs to the STN may be altered (Magill et al., 2001; Magill et al., 2004; Sharott et al., 2005; Kühn et al., 2006; Mallet et al., 2008; Litvak et al., 2011; Moran et al., 2011; Alegre and Valencia, 2013). Furthermore, exogenous activation of the corticostriatal projection can induce Parkinsonian motor symptoms in rodents (Pan et al., 2014), indicating that glutamatergic neurotransmission in the STN has an integral role in basal ganglia function and movement.

Subthalamic neurons express mRNA encoding subunits in each ionotropic glutamate receptor class, including AMPA, kainate, and NMDA receptors (Sato et al., 1993; Bischoff et al., 1997; Wüllner et al., 1997; Clarke and Bolam, 1998; Jakowec et al., 1998). AMPA/kainate-type receptors mediate the fast component of EPSCs, whereas NMDA receptors mediate the slow component, which carries the majority of charge transfer and calcium influx during excitatory neurotransmission (Traynelis et al., 2010). NMDA receptors are typically composed of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits (Dingledine et al., 1999; Karakas and Furukawa, 2014; Lee et al., 2014). The GluN2 subunits, GluN2A–D, confer distinct properties to the receptor, including pharmacology, deactivation time course, channel open probability, and sensitivity to magnesium inhibition (Traynelis et al., 2010). For example, GluN2D-containing NMDA receptors have a strikingly slow deactivation time course, low single channel open probability, and weak magnesium sensitivity compared with the other GluN2 subunits. In addition, GluN2 subunits have different regional expression patterns in the brain and in situ hybridization studies suggest that subthalamic neurons express mRNA encoding GluN2B and GluN2D (Monyer et al., 1994; Standaert et al., 1994; Wenzel et al., 1996). Agonist-evoked AMPA and NMDA receptor currents have been demonstrated in STN neurons (Götz et al., 1997; Awad et al., 2000; Lobo et al., 2003), but the roles for specific ionotropic glutamate receptors in synaptic transmission and spike firing in the STN have not been studied in detail.

The goal of this study was to determine which glutamate receptor subtypes mediate excitatory synaptic transmission in the STN, with a particular focus on determining the contribution of GluN2D-containing NMDA receptors. In addition, we tested whether modulating GluN2D-containing receptors influenced STN spike firing in vivo. Our results indicate that GluN2B- and GluN2D-containing receptors mediate the NMDA receptor component of EPSCs in the STN and that ongoing activation of GluN2D-containing NMDA receptors affects STN spike firing in vivo. These findings have important implications for the potential therapeutic regulation of STN spike activity.

Materials and Methods

Tissue punches and Western blotting. All procedures using animals were approved by the Institutional Animal Care and Use Committee of Emory University. Female Sprague Dawley rats [age postnatal day 7 (P7), P14, P30, P60, and P110–P120] and WT and GluN2D−/− C57BL/6 mice of both sexes (age P28–P30) were killed by isoflurane overdose (Ikeda et al., 1995). The brains were removed and 200–300 μm sagittal slices containing the STN were prepared in ice-cold PBS using a vibrating microtome. Tissue punches of the STN were removed using a 0.5 or 0.75 mm tissue punch (Stoelting) and then frozen on dry ice. The tissue was sonicated in lysis buffer, pH 7.4, containing the following (in mM): 150 NaCl, 50 Tris, 50 NaF, 5 EDTA, 1 EGTA, 1% Triton, 1% SDS, and protease inhibitors. Protein concentrations were determined by the Bradford assay and then the samples were diluted with lysis buffer and 2× Laemmli buffer to a final concentration of 0.5 μg/μl. After heating at 95°C for 5 min, 5–10 μg of total protein was loaded on a 4–15% SDS-PAGE gel. Proteins were transferred to PVDF membranes for Western blotting. The antibodies used were mouse anti-GluN2D (Millipore, MAB5578, 1:5000), mouse anti-tubulin (Sigma-Aldrich, 1:50,000), and HRP-conjugated goat antibody (Jackson Immunoresearch, 1:10,000). Membranes were stripped with Restore Stripping Buffer ( Pierce) for 15 min and washed before being reprobed with additional primary antibodies. Chemiluminescence signals were detected with film, which were imaged with the Bio-Rad Gel Doc Imaging System and analyzed by densitometry using ImageJ.

Immunohistochemistry and electron microscopy. Adult Sprague Dawley rats and adult WT and GluN2D−/− C57BL/6 mice of both sexes were used for histology experiments. The animals were anesthetized with pentobarbital and perfusion fixed with a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde (Galvan et al., 2006; Kuwajima et al., 2007). The brains were then cut into 60-μm-thick sections with a vibratome and processed for the light and electron microscopic localization of the GluN2D subunit using well characterized commercially available antibodies: mouse anti-GluN2D (Millipore, MAB5578) or goat anti-GluN2C/D (Santa Cruz Biotechnology, sc-31551; Laurie et al., 1997). The avidin–biotin peroxidase method and 3,3′ diaminobenzidine were used to visualize the reaction product of GluN2D immunoreactivity. Sections of the STN were prepared for electron microscopy as previously described (Kuwajima et al., 2004; Galvan et al., 2006; Kuwajima et al., 2007). One block of tissue was taken out from the STN in each animal, cut in ultrathin sections with an Ultracut T2 (Leica), mounted on copper grids, and examined in the electron microscope at the electron microscopic level, the STN tissue was scanned, and a series of 50 micrographs of randomly distributed immunoreactive profiles were taken at 40,000×. The different labeled elements were categorized as dendrites, terminals, axons, or glia according to their ultrastructural features (Peters et al., 1991).

Cell culture and molecular biology. Cells from the human embryonic kidney-293 cell line (CRL 1573; ATCC; hereafter HEK cells) were plated on glass coverslips (Warner Instruments) coated with 100 μg/ml poly-d-lysine. Cells were maintained in 5% humidified CO2 at 37°C in Dulbecco’s Modified Eagle Medium with Glutamax (Invitrogen) supplemented with 10% fetal bovine serum, 10 units/ml penicillin, and 10 μg/ml streptomycin. The Fugene6 transfection reagent (Roche Diagnostics) was used to transiently transfect HEK cells with cDNA encoding GFP, GluN1, and GluN2 at a ratio of 1:1:1. The cDNAs used were rat NMDA receptor subunits GluN2B (GenBank U11419), GluN2D (GenBank L31611), GluN1-1a (GenBank U11418, U08261), and GluN1-1b (GenBank U08263). The transfected cells were incubated in media supplemented with NMDA receptor antagonists 2,2-diamino-5-phosphonovalerate (200 μM; D-APV) and 7-chlorokynurenic acid (200 μM; 7-CKA).

Patch-clamp recordings from transfected HEK cells. Voltage-clamp recordings were made from transfected cells lifted from the coverslip (Vrest = 60 mV, Axopatch 200B amplifier; Molecular Devices). Recordings were digitized at 40 kHz using Axon pClamp10 software and filtered at 8 kHz using an eight-pole Bessel filter (~3 dB; Frequency Devices). Electrodes were made from thin-walled borosilicate glass (Warner Instruments) and were filled with an internal solution containing the following
(in mM): 110 Cs-glutamate, 30 CaCl₂, 5 HEPES, 4 NaCl, 0.5 CaCl₂, 2 MgCl₂, 5 BAPTA, 2 Na₂ATP, and 0.3 NaGTP, pH 7.35, 295 MΩ. Cells were bathed in an external solution containing the following (in mM): 150 NaCl, 10 HEPES, 30 m-mannitol, 3 KCl, 0.5 CaCl₂, and 0.01 EDTA, pH 8.0. A Warner Instruments TC-344B temperature controller maintained the temperature of the external solution (23°C ± 3°C). Rapid solution exchange for whole-cell voltage-clamp recordings of HEK cells was performed using a two-barrel theta glass pipette controlled by a piezoelectric translator (Burleigh Instruments). The open tip 10–90% rise time of the solution exchange was <0.6 ms and the solution exchange time (10–90%) around a whole cell was ~3 ms (Vance et al., 2012).

Patch-clamp recording from neurons in the STN. Sprague Dawley rats (aged P11–P18) as well as WT or GluN2D−/− C57BL/6 mice (aged P14–P20) of both sexes were killed by isoflurane overdose and decapitated. The brain was rapidly removed, hemisected, and glued to the stage of a vibrating microtome (Leica VT1000S or VT1200S). Sagittal brain slices (250 μm) were cut in ice-cold artificial CSF (aCSF) composed of (in mM): 130 NaCl, 24 NaHCO₃, 10 glucose, 3 KCl, 3 MgSO₄·7H₂O, and 1 CaCl₂ that was saturated with 95% O₂/5% CO₂. For some experiments, after isoflurane overdose, the animals were transcardially perfused with a solution containing (in mM): 110 CsCl, 5 BAPTA, 2 Na₂ATP, and 0.3 NaGTP, pH 7.35, 295 MΩ.

Recording electrodes were continuously evoked by pressure application of NMDA and glycine. After bath application of the modulator, the slice was washed 10–90 s intervals. The NMDA receptor modulator (prepared in the aCSF external solution) or vehicle was bath applied for 5–15 min while curative antagonists were continuously evoked by pressure application of NMDA and glycine. After bath application of the modulator, the slice was washed off the control aCSF solution and NMDA/glycine continued to be pressure applied at the same interval. Finally, the NMDA receptor competitive antagonist D,L-APV (400 μM) was bath applied during NMDA and glycine applications to inhibit the NMDA receptor response (Lee et al., 2007).

EPSCs were evoked by injecting 50–500 μA of current for 0.1 ms using a bipolar tungsten-stimulating electrode (FHC) placed near the internal capsule fibers rostral to the STN (Baufreton et al., 2009; Yamawaki et al., 2012). EPSCs were evoked every 30 s and the recordings were conducted using the external solution described above supplemented with 10 μM bicuculline and 10 μM DNQX. Voltage-clamp recordings were performed at −40 mV or +40 mV with 0.2 ms or 1.5 ms Mg²⁺, respectively, in the recording solutions. Paired-pulse recordings were performed at −40 mV in 10 μs bicuculline, 1 ms Mg²⁺, and 4 ms Ca²⁺. For the paired-pulse recordings, EPSCs were evoked every 30 s by a pair of stimuli separated by 50 ms. The Iₚ current was recorded under current-clamp conditions using the same intracellular solution by injecting 0.1 nA of hyperpolarizing current into the cell for 1 s. Attenuation voltage-clamp recordings. The individual sweeps of whole-cell voltage-clamp recordings from HEK cells and subthalamic neurons were averaged and preapplication baseline subtracted. Clampfit was used to determine current amplitude, the 10–90% rise time of peak amplitude, charge transfer, and the deactivation time constants. The deactivation time constants of whole-cell voltage-clamp recordings from HEK cells and evoked EPSCs from subthalamic neurons were calculated by fitting the following equation to the data:

\[ \text{Response} = \text{Amp}_{\text{FAST}} \exp (-t/\tau_{\text{FAST}}) + \text{Amp}_{\text{SLOW}} \exp (-t/\tau_{\text{SLOW}}) \]

Where \( \tau_{\text{FAST}} \) is the fast deactivation time constant, \( \tau_{\text{SLOW}} \) is the slow deactivation time constant, \( \text{Amp}_{\text{FAST}} \) is the current amplitude of the fast deactivation component, and \( \text{Amp}_{\text{SLOW}} \) is the current amplitude of the slow deactivation component. Weighted deactivation time constants (\( \tau_w \)) were calculated using the following equation:

\[ \tau_w = \frac{\text{Amp}_{\text{FAST}}}{\text{Amp}_{\text{FAST}} + \text{Amp}_{\text{SLOW}}} \tau_{\text{FAST}} + \frac{\text{Amp}_{\text{SLOW}}}{\text{Amp}_{\text{FAST}} + \text{Amp}_{\text{SLOW}}} \tau_{\text{SLOW}} \]

In vivo extracellular recordings of STN neuronal activity. All in vivo rat spike-firing experiments were performed in accordance with the European Communities Council Directive (86/609/EEC) for the care and use of laboratory animals and the Danish legislation regulating animal experiments. The Danish Animal Experiments Inspectorate approved the protocols (journal no 2004/561–798). For all experiments, rats were housed two per cage under a 12 h light/dark cycle (lights on at 6:00 A.M.) in a temperature (21 ± 2°C) and humidity (60 ± 10%)-controlled environment. Rats were allowed to acclimatize for 5–7 d before experimentation with ad libitum access to rat chow and tap water.

For recordings of neurons in the STN, male Wistar rats (Charles River) weighing 280–360 g were used. Animals were anesthetized with an intraperitoneal injection of urethane (1.2–1.5 g/kg). Animals were then maintained in a stereotaxic frame, the skull was exposed, and a hole ~3 × 3 mm was drilled above the STN (see coordinates below). Extracellular single-cell recordings were performed using an assembly consisting of a recording glass electrode and an ejection pipette allowing local drug delivery. The recording glass micropipette was first pulled and broken at an external diameter of 2–4 μm and was subsequently bent by heating the shank ~7 mm from the tip. The ejection pipette was prepared from glass tubing with an internal diameter of 0.3 mm and calibrated at 15 mmHg/μL (Assistent, ref. 555/5) and was pulled and broken back to an external diameter of 50 μm. The ejection pipette then was positioned under microscopic control and, by means of micromanipulators, immediately adjacent to and 40–60 μm above the tip of the recording electrode. Both pipettes were permanently jointed with an ultraviolet-sensitive resin. Ejection pipettes were filled through the tip by negative pressure with NMDA modulators at various concentrations dissolved in PBS solution (NaCl 8 g/L, KCl 0.2 g/L, Na₂HPO₄·2H₂O 1.44 g/L, KH₂PO₄ 0.2 g/L, and CaCl₂·2H₂O 132 mg/L). The recording electrode was filled with 2% (w/v) Pontamine Sky Blue in 0.5 mM sodium acetate solution and had an impedance of 2–10 MΩ at 135 Hz.

The assembly was then lowered into the brain using a hydraulic microdrive at the following coordinates: AP 4.2–3.6 mm posterior to bregma; L 2.2–2.8 mm lateral to the midline. Extracellular action potentials were amplified, discriminated, and monitored on an oscilloscope and an audiometer. Discriminated spikes were collected and analyzed using Spike 2 software (Cambridge Electronic Design) on a PC-based system connected to a CED 1401i interface unit (Cambridge Electronic Design). Presumed glutamatergic neurons from the STN typically were found 7.4–8.0 mm beneath the surface of the brain according to the rat brain atlas (Paxinos and Watson, 1998) and all exhibited a biphasic, positive-negative waveform. Once a neuron was isolated and its baseline firing rate was stable for at least 5 min, drug application close to the recorded neuron was initiated by applying repeated pressure pulses (10–40 ms duration; 10–20 psi) with the assistance of a Picospritzer III (Intracell). A small volume (3–6 nl) typically was applied to minimize mechanical distortion and was followed under microscopic control by the movement of the solution meniscus in the pipette. Repeated ejections...
were performed to assess reproducibility of the drug effects at a minimum interval of 4 min.

The NMDA receptor modulator CIQ was either applied alone (10-20 μM) or in combination with MK-801 (2.5 μM). The change in firing rate induced by drug application was compared with the baseline firing rate by measuring the maximal firing rate during either the last 10–20 s of drug application for CIQ or the 10–20 min period after DQP-1105 application, which was then expressed as percentage of baseline firing rate measured 3–5 min before drug application. For MK-801 coapplication experiments, because a decrease in the baseline firing rate typically was observed over time after MK-801 application, the baseline firing rate measured before each drug application was subtracted from the maximal firing rate during the last 10–20 s of drug application. The responses evoked by the second through fifth applications were then expressed as a percentage of the response evoked by the first drug application.

Statistical analysis. The data were analyzed and plotted in GraphPad Prism 5 or Origin Lab 9.0. The Shapiro–Wilk’s test was used to test for normality and Levene’s test was used to test for homogeneity of variances. The data were then analyzed using appropriate parametric or non-parametric tests with corrections for multiple comparisons as stated in the figure legends. Normal data are reported as mean ± SEM and non-normal data are reported as median and 25–75% interquartile range (IQR). Significance for all tests was set at p < 0.05.

Results

GluN2D subunit is expressed in subthalamic neurons

GluN2D expression levels are developmentally regulated in some brain regions, many of which show a marked decrease in expression during postnatal development (Duah et al., 1996; Wenzel et al., 1996; Laurie et al., 1997; Lau et al., 2003; Shibata et al., 2003; Liu and Wong-Riley, 2010). To evaluate GluN2D expression in the STN, tissue punches were harvested from the STN of rats aged P7, P14, P30, P60, and P110–P120 (Fig. 1A) and then analyzed by Western blotting using a monoclonal antibody against GluN2D. GluN2D expression was observed in the STN at all of the ages analyzed in this study and there was no significant change in GluN2D levels between age groups (n = 3–4 animals per group; Fig. 1B, C). Tissue punches from WT and GluN2D−/− mice (Ikeda et al., 1995) were used to demonstrate the specificity of the GluN2D antibody (n = 3 animals; Fig. 1C). Importantly, these data demonstrate that the GluN2D subunit is expressed in the rat STN throughout postnatal development and in adulthood. In addition, brain sections from WT and GluN2D−/− mice were immunostained with a polyclonal antibody that detects the GluN2C and GluN2D subunits. Using light microscopy, strong immunoreactivity was apparent in WT STN, whereas the faint immunoreactivity was expressed predominantly in dendrites of subthalamic neurons and could regulate synaptic transmission in the STN.

Agonist-evoked NMDA receptor currents in the STN are mediated by GluN2B- and GluN2D-containing receptors

To determine which GluN2 subunits contributed to NMDA receptor currents in subthalamic neurons, we tested the effects of GluN2 subunit-selective modulators on agonist-evoked responses in brain slices from rats aged P11–P18. NMDA (1 mM) and glycine (0.5 mM) were ejected from a micropipette by brief pressure pulses and NMDA receptor modulators were bath applied to the slices (Fig. 3A). The GluN2B-selective inhibitor ifenprodil (3 μM; Williams, 1993) reduced the peak amplitude of NMDA- and glycine-evoked currents to 62 ± 8.1% of the baseline response in aCSF (n = 6; Fig. 3B, C). Next, we tested whether agonist-evoked currents could be modulated by the GluN2C/D-selective inhibitor DQP-1105 (Acker et al., 2011) and GluN2C/D-selective positive allosteric modulator CIQ (Mullasseril et al., 2010). DQP-1105 (20 μM) inhibited current amplitudes to 14.3 ± 2.3% total labeled elements, respectively; Fig. 2C,E) and axon terminals (17.3 ± 2.8% and 23.3 ± 1.4% total labeled elements, respectively), some of which displayed the ultrastructural features of putative pallidal GABAergic terminals (Fig. 2A,F). Occasional, the peroxidase deposit in the labeled dendrites was aggregated at the postsynaptic densities of asymmetric synapses (Fig. 2B,D). Overall, the patterns of STN labeling obtained with both the polyclonal GluN2C/D and the monoclonal GluN2D antibodies were similar despite the different epitopes of the two antibodies (Fig. 2G). Altogether, these data provide strong evidence that GluN2D is expressed in subthalamic neurons and could regulate synaptic transmission in the STN.

Figure 1. GluN2D protein expression during postnatal development. A, Brain slices are shown before (left) and after (right) removal of the STN by a tissue punch. B, GluN2D expression in STN tissue punches obtained from rats aged P7, P14, P30, P60, and P110–P120 (P110 +) was evaluated by Western blot. Densitometry measurements for GluN2D levels were normalized to tubulin levels, plotted as mean ± SEM, and analyzed by one-way ANOVA (n = 3–4 animals per group, F(4,11) = 2.153, p = 0.142). Measurements from two replicate Western blots were averaged for each animal. C, Representative Western blots of GluN2D and tubulin show protein samples from two different animals for each age group. D, Immunoperoxidase labeling from polyclonal GluN2C/D antibodies is shown in the STN of WT mice (left) and GluN2D−/− mice (center). The right panel shows peroxidase labeling in WT tissue incubated without primary antibodies. Scale bar, 0.5 mm.
65.0 ± 5.5% of baseline responses (n = 6; Fig. 3B,D), and CIQ (20 μM) potentiated current amplitudes to 150 ± 8.6% of baseline aCSF responses (n = 6; Fig. 3B,E). In addition, we evaluated whether the GluN2A-selective inhibitor TCN-201 affected agonist-evoked responses in the STN (Bettini et al., 2010; Edman et al., 2012; Hansen et al., 2012). We used 3 μM glycine because TCN-201 has been shown to be less effective at higher concentrations of glycine (Hansen et al., 2012). TCN-201 did not affect the peak amplitude of the currents (100 ± 3.2% of baseline, n = 6; Fig. 3B) compared with the vehicle control (102 ± 2.2% of baseline, n = 5). As a positive control, TCN-201 significantly reduced NMDA receptor currents recorded from cerebellar granule cells cultured in elevated potassium, which is known to promote expression of GluN2A (31 ± 3.9% of control, n = 7, paired t test, p = 0.006; Zheng et al., 2001). In each experiment, the agonist-evoked responses were blocked by application of D,L-APV, indicating that the currents were mediated by NMDA receptors (e.g., Fig. 3C–E). We interpret these data to suggest that the GluN2B and GluN2D subunits are the primary GluN2 subunits expressed in the developing rat STN, which is consistent with previous reports showing GluN2B and GluN2D mRNA expression in the STN (Monyer et al., 1994; Standaert et al., 1994).

**STN EPSCs are mediated by AMPA and NMDA receptors**

To assess how ionotropic glutamate receptors contribute to synaptic currents in the STN, EPSCs were evoked using a stimulating electrode placed in the internal capsule and the NMDA, AMPA, and kainate receptor components of the EPSC were isolated pharmacologically (Fig. 4A; Baufreton et al., 2009). We first assessed the Mg$^{2+}$ sensitivity of the NMDA receptor component (NMDAR-EPSCs) by evaluating the current–voltage relationship for EPSCs at 0.2 mM and 1.5 mM Mg$^{2+}$ in the presence of the AMPA/kainate receptor antagonist DNQX (n = 4; Fig. 4B). NMDAR-EPSCs showed moderate voltage-sensitive Mg$^{2+}$ block when recorded at −40 mV in aCSF containing 0.2 mM Mg$^{2+}$ compared with that observed at 1.5 mM Mg$^{2+}$. Therefore, we determined the total contribution of NMDA receptors to synaptic currents by applying DNQX (20 μM) and evoking EPSCs at a holding potential of +40 mV with 1.5 mM Mg$^{2+}$. After DNQX application, the peak amplitude of the remaining EPSC was 53.7% (median) of the baseline EPSC amplitude in aCSF (IQR = 24.3−63.8, n = 14; Fig. 4C,D). In addition, DNQX slowed the EPSC deactivation time course compared with the aCSF control (Table 1), which is consistent with NMDA receptors mediating the slow component of the EPSC time course in the STN.

AMPA and kainate receptor currents were isolated by inhibiting NMDA receptors with 400 μM D,L-APV and 50 μM 7-CKA, which reduced the peak current to 36.7% (median) of the baseline EPSC amplitude in aCSF (IQR = 27.0−47.0%, n = 8; Fig. 4C,D). As expected, inhibition of NMDA receptors significantly accelerated the decay time for the EPSC (Table 1). To study the contribution of kainate receptors alone, we applied 400 μM D,L-APV and 50 μM 7-CKA (to inhibit NMDA receptors) plus 100 μM GYKI-52466, a selective noncompetitive antagonist for AMPA receptors (Mott et al., 2008). Under these conditions, we detected a residual postsynaptic current in four of eight neurons tested. The peak amplitude of the remaining currents had a median value of 10.7% of the baseline response in aCSF (IQR = 5.4−19.2%, n = 4) and these remaining currents were subsequently blocked by AMPA/kainate receptor antagonist DNQX, suggesting that they may be mediated by kainate receptors. In the other four neurons, inhibition of only NMDA and AMPA receptors blocked the entire EPSC, suggesting that kainate receptors are not expressed at all synapses in the STN. The overall median of kainate receptor responses was 2.2% of the total EPSC amplitude, which was not significantly different from zero (IQR = 0−11.7%, n = 8, Wilcoxon’s signed-rank test, p = 0.125). The deactivation time course of kainate receptor currents was faster than that of the total EPSC, but not significantly different from the combined AMPA/kainate receptor response (Table 1). Therefore, it is poss-
Figure 3. NMDA- and glycine-evoked currents are potentiated or inhibited by GluN2B and GluN2D subunit-specific modulators. A, Brief pulses (3–100 ms) of NMDA (1 mM) and glycine (0.003–0.5 mM) were pressure applied to STN neurons in acute brain slices and current responses were recorded by whole-cell voltage-clamp (V_{HOLD} = −60 mV). B, Effects of bath application of TCN-201 (10 μM), ifenprodil (3 μM), DQP-1105 (20 μM), CIQ (20 μM), and vehicle (0.1% DMSO) on the peak amplitudes of current responses were plotted as the percentage of baseline aCSF responses. Open gray circles represent individual values, the horizontal black lines represent the period of drug application. C, The black bars depict the period of drug application.

Figure 4. NMDA and AMPA receptors mediate the majority of EPSCs in the STN. A, Representative recording arrangement used to evoke EPSCs with a bipolar tungsten-stimulating electrode placed in the internal capsule rostral to the STN. B, The current–voltage relationships for the NMDA component of STN EPSCs were acquired in the presence of 20 μM DNX2 and either 0.2 mM Mg^2+ (n = 4) or 1.5 mM Mg^2+ (n = 4). The currents were normalized to the peak EPSC amplitudes recorded at +60 mV for each condition. C, In the representative trace, AMPA and kainate receptors were isolated by bath application of 400 μM DNP-52466, 400 μM ifenprodil, 3 μM DNP-1105, and 50 μM 7-CQA (gray). Kainate receptors (dark gray) were isolated by bath application of 100 μM GYKI-52466, 400 μM ifenprodil, and 50 μM 7-CQA. The NMDA receptor component (light gray) was determined by subtracting the EPSC response recorded in the presence of 400 μM ifenprodil and 50 μM 7-CQA from the total evoked EPSC recorded in aCSF alone (black). D, Comparison of the peak responses of evoked EPSCs in the presence of DNX (NMDA, n = 14), L-APV and 7-CQA (AMPA/KAR, n = 8), or GYKI-52466, ifenprodil, and 7-CQA (KA, n = 8) are shown as a percentage of total EPSC amplitude. n is the number of brain slices. The horizontal line is the median value, the box is the 25–75 percentile, and the whiskers are the 10–90 percentile.

Table 1. Deactivation time courses of subthalamic EPSCs

<table>
<thead>
<tr>
<th>Receptor EPSC</th>
<th>τ_{FAST} (ms)</th>
<th>τ_{MID} (ms)</th>
<th>τ_{SLOW} (ms)</th>
<th>% τ_{FAST}</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>36 ± 4.4</td>
<td>240 ± 43</td>
<td>109 ± 10</td>
<td>58 ± 3.3</td>
<td>25</td>
</tr>
<tr>
<td>NMDAR</td>
<td>53 ± 12</td>
<td>268 ± 39</td>
<td>154 ± 16*</td>
<td>49 ± 5.8</td>
<td>13</td>
</tr>
<tr>
<td>AMPAR/KAR</td>
<td>11 ± 1.9</td>
<td>73 ± 12</td>
<td>27 ± 3.6*</td>
<td>71 ± 4.3</td>
<td>11</td>
</tr>
<tr>
<td>KAR</td>
<td>15 ± 2.0</td>
<td>86 ± 13</td>
<td>26 ± 1.8*</td>
<td>81 ± 3.9</td>
<td>8</td>
</tr>
</tbody>
</table>

τ_{val} values were compared by one-way ANOVA (F_{(4,24)} = 12.57, p < 0.001) and post hoc Tukey’s tests (*p = 0.029, †p < 0.001 vs total, n is the number of slices.

GluN2B- and GluN2D-containing receptors mediate the NMDA receptor component of EPSCs in the STN

to determine the contributions of the GluN2B and GluN2D subunits to synaptic activity in the STN, EPSCs were evoked in the presence of GluN2B- or GluN2D-selective NMDA receptor modulators. The GluN2B-selective antagonist ifenprodil (3 μM) significantly reduced the peak amplitude and total charge transfer of the EPSCs to 67 ± 6.5% and 66.5 ± 6.1% of baseline EPSCs, respectively (n = 14; Fig. 5A, D,E). The GluN2C/D-selective inhibitor DQP-1105 (20 μM) significantly decreased the peak amplitude and the total charge transfer of the current responses to 59 ± 8.4% and 62 ± 12% of baseline aCSF responses, respectively (n = 7; Fig. 5B, D,E). The GluN2C/D-positive allosteric modulator CIQ (20 μM) increased the peak amplitude and total charge transfer of evoked currents to 156 ± 13% and 137 ± 10% of baseline responses, respectively (n = 13; Fig. 5C–E). The vehicle control (0.1% DMSO) did not affect the peak amplitude (99 ± 3.2%, n = 12; Fig. 5D) or the total charge transfer (98 ± 4.9%; Fig. 5E) of EPSCs. These data suggest that NMDA receptors containing the GluN2B and GluN2D subunits mediate excitatory synaptic currents in the STN.

To demonstrate the specificity of the GluN2C/D-selective modulators used in this study, EPSCs were evoked in STN slices...
from WT and GluN2D−/− mice in the absence and presence of DQP-1105 and CIQ. In WT neurons, DQP-1105 significantly reduced the total charge transfer of EPSCs to 69.5 ± 3.0% of baseline (Fig. 5F,G) and the peak amplitude of EPSCs was reduced to 74.4 ± 4.4% of baseline (n = 3, paired t test, p = 0.006). DQP-1105 had no significant effect on EPSC charge transfer (97.9 ± 4.4% of baseline; Fig. 5F,G) or peak amplitude in GluN2D−/− neurons (106 ± 2.9% of baseline, n = 4, paired t test, p = 0.169). CIQ significantly increased EPSC total charge transfer (140 ± 7.4% of baseline; Fig. 5H,I), as well as peak amplitude in WT neurons (118 ± 0.1% of baseline, n = 3, paired t test, p = 0.002). However, in GluN2D−/− neurons, CIQ had no significant effect on EPSC total charge transfer (109 ± 5.0% of baseline; Fig. 5H,I) or peak amplitude (99.8 ± 8.7% of baseline, n = 3, paired t test, p = 0.428). These data provide evidence that the effects of the GluN2C/D-selective modulators were mediated by GluN2D-containing NMDA receptors in the STN.

GluN2D immunoreactivity was occasionally detected in axon terminals synapsing upon the STN; therefore, we also evaluated whether the GluN2D subunit had a presynaptic effect on EPSCs by testing whether the paired-pulse ratio was altered by potentiation of GluN2D-containing NMDA receptors with CIQ. The paired-pulse ratio was 1.4 ± 0.10 in aCSF with a 50 ms interval between pulses and bath application of 20 μM CIQ did not significantly alter the paired-pulse ratio (1.5 ± 0.13, n = 5, paired t test, p = 0.239). These data suggest that potentiation of GluN2D-containing NMDA receptors does not alter presynaptic glutamate release.

Loss of GluN2D function accelerates the EPSC deactivation time course in the STN

NMDA receptors containing GluN2D have slower deactivation kinetics compared with the other GluN2 subunits (Traynelis et al., 2010), raising the possibility that GluN2D expression would slow the decay time of EPSCs in the STN. To test this hypothesis, we compared the deactivation time constants for EPSCs evoked at baseline in aCSF to those after application of subunit-selective modulators. DQP-1105 significantly decreased the time constant...
GluN2D Function in the Subthalamic Nucleus

Table 2. EPSP deactivation time course is accelerated by GluN2D inhibition

<table>
<thead>
<tr>
<th></th>
<th>aCSF</th>
<th>Iifenprodi</th>
<th>aCSF</th>
<th>DQP-1105</th>
<th>aCSF</th>
<th>CIQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \tau_{\text{FAST}} ) (ms)</td>
<td>41 ± 5.2</td>
<td>48 ± 5.1</td>
<td>59 ± 14</td>
<td>43 ± 13</td>
<td>55 ± 6.7</td>
<td>65 ± 10</td>
</tr>
<tr>
<td>( \tau_{\text{SLOW}} ) (ms)</td>
<td>277 ± 35</td>
<td>301 ± 45</td>
<td>304 ± 45</td>
<td>211 ± 21*</td>
<td>310 ± 52</td>
<td>329 ± 78</td>
</tr>
<tr>
<td>( \tau_{\text{W}} ) (ms)</td>
<td>149 ± 20</td>
<td>176 ± 22</td>
<td>153 ± 17</td>
<td>177 ± 12*</td>
<td>148 ± 15</td>
<td>148 ± 16</td>
</tr>
<tr>
<td>% ( \tau_{\text{FAST}} )</td>
<td>55 ± 5.0</td>
<td>46 ± 7.4</td>
<td>59 ± 7.4</td>
<td>60 ± 8.0</td>
<td>56 ± 5.3</td>
<td>62 ± 4.4</td>
</tr>
</tbody>
</table>

Time constants were analyzed by one-way ANOVAs: \( \tau_{\text{FAST}}; F_{2,22} = 2.356, \ p = 0.053; \tau_{\text{SLOW}}; F_{2,22} = 4.01, \ p = 0.016; \tau_{\text{W}}; F_{2,22} = 3.54, \ p = 0.021; \% \tau_{\text{FAST}}; F_{2,22} = 0.876, \ p = 0.464 \) and post hoc Bonferroni comparisons were performed between control drug (ifenprodi: \( \tau_{\text{SLOW}}; p = 0.541, \tau_{\text{W}}; p = 0.139, \) DQP-1105: \( p = 0.037, \ p = 0.004; \) CIQ: \( \tau_{\text{W}}; p = 0.961, \ p = 0.527 \)). The reported values are mean ± SEM. \( n \) is the number of slices.

Table 3. EPSP deactivation time course is accelerated in the STN of GluN2D \( ^{−/−} \) mice

<table>
<thead>
<tr>
<th>Genotype</th>
<th>( \tau_{\text{FAST}} ) (ms)</th>
<th>( \tau_{\text{SLOW}} ) (ms)</th>
<th>( \tau_{\text{W}} ) (ms)</th>
<th>% ( \tau_{\text{FAST}} )</th>
<th>( n )</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>150 ± 10</td>
<td>61.1 ± 7.6</td>
<td>338 ± 44</td>
<td>62.5 ± 5.8</td>
<td>7</td>
</tr>
<tr>
<td>GluN2D ( ^{−/−} )</td>
<td>67.8 ± 12*</td>
<td>32.6 ± 7.2*</td>
<td>144 ± 27*</td>
<td>65.1 ± 7.8</td>
<td>6</td>
</tr>
</tbody>
</table>

Time constants were compared between WT and GluN2D \( ^{−/−} \) groups by Student’s t test: \( p = 0.02, \ p = 0.004, \ p = 0.004, \% \tau_{\text{FAST}} \) was not significant \( (p = 0.792) \). The reported values are mean ± SEM \( n \) is the number of slices.

NMDA receptor deactivation rates in the STN are consistent with recombinant GluN2B- and GluN2D-containing receptors

Given that NMDA receptors containing distinct subunits have different deactivation rates, we evaluated whether the time course obtained for the NMDA receptor component of EPSCs in the STN was consistent with the deactivation time course of recombinant GluN2B- or GluN2D-containing NMDA receptors. For these experiments, we transiently transfected HEK cells with GluN2B or GluN2D, along with GluN1-1a or GluN1-1b. These two different splice variants of GluN1 were used because the variants containing exon 5 (GluN1-1b/2b/3b/4b) have been proposed to be expressed in STN neurons and exons 5-containing NMDA receptors have an accelerated deactivation time course after glutamate removal (Standaert et al., 1993; Laurie and Seeburg, 1994; Winkler et al., 1999; Rumbaugh et al., 2000; Vance et al., 2012).

The recombinant NMDA receptors were activated by rapid application of 1 mM l-glutamate for 2–4 s (0.05 mM glycine was present in all solutions) and the deactivation time constant was determined upon rapid removal of l-glutamate. To compare the time courses with those obtained from evoked NMDAR-EPSCs in STN slices, we evaluated the temperature sensitivity of recombinant NMDA receptor deactivation by recording at both 23°C and 32°C. As expected, the deactivation time course of recombinant NMDA receptors was accelerated at 32°C compared with recordings obtained at 23°C (Fig. 6A, Table 4), similar to what has been observed previously for NMDA receptors (Cais et al., 2008). Furthermore, GluN1-1b/GluN2B receptors had a more rapid deactivation time course compared with GluN1-1a/GluN2B receptors (Fig. 6A, Table 4; see also Vance et al., 2012). Likewise, the deactivation time course of GluN1-1b/GluN2D receptors was significantly faster than that of GluN1-1a/GluN2D receptors (Fig. 6A, Table 4). Notably, the deactivation time course observed for the NMDA receptor component of EPSCs in the STN is intermediate between the deactivation time components of recombinant GluN1-1b/GluN2B and GluN1-1b/GluN2D at 32°C (Fig. 6B, Table 1, 4). This result is consistent with the hypothesis that NMDA receptors containing GluN2B and/or GluN2D subunits mediate EPSCs in the STN.

GluN2D modulators alter spike firing in vivo

GluN2D-containing receptors could contribute to the resting excitability in the STN due to their high sensitivity to glutamate,
The effect of CIQ on spike firing was transient and reversible and significantly attenuated by the NMDA receptor channel blocker MK-801 (n = 4; Fig. 7J). Together, these data suggest that GluN2D-containing NMDA receptors have an important role in regulating spike firing of subthalamic neurons in vivo and that the GluN2D subunit may be a useful pharmacological target for modulating STN activity.

### Discussion

Three main findings of this study demonstrate the potential role of GluN2D-containing NMDA receptors in regulating excitatory synaptic transmission in the rat STN. First, the GluN2D subunit is expressed presynaptically and postsynaptically in subsets of dendrites, axons, and axon terminals in the rat STN. Second, the GluN2D and GluN2B subunits are the predominant GluN2 subunits mediating NMDA receptor function in the developing rat STN. Third, modulation of GluN2D-containing NMDA receptors controls in vivo spike firing in the adult rat STN. These data identify the functional contributions of NMDA receptor sub-
types to synaptic currents and suggest a key role for the GluN2D subunit in regulating neuronal activity in the STN.

The recent development of pharmacological tools that modulate GluN2D-containing receptors has allowed for functional studies of GluN2D in the nervous system. In the STN, we observed a partial inhibition of EPSCs by the GluN2C/D-selective negative allosteric modulator DQP-1105, which is 40- to 70-fold selective for GluN2D over GluN2A/B (Acker et al., 2011). DQP-1105 has also been used to demonstrate GluN2D function at synapses in the spinal cord dorsal horn and the SNc (Hildebrand et al., 2014; Pearstein et al., 2015). EPSCs in the striatum were partially inhibited by the GluN2C/D-selective inhibitor QNZ46, which is ~50-fold selective for GluN2D over GluN2A/B (Mosley et al., 2010; Hansen and Traynelis, 2011). The GluN2C/D-selective positive allosteric modulator CIQ (Mullasseril et al., 2010) potentiated subthalamic EPSCs in our study and CIQ likely modulated spike firing and dopamine levels in the striatum (Feng et al., 2014; Zhang et al., 2014). In these studies, it was inferred that the effects of GluN2C/D modulators were mediated by GluN2D, not GluN2C, due to the lack of histological evidence for GluN2C expression in these brain regions (Monyer et al., 1994; Standaert et al., 1994; Wenzel et al., 1996; Wenzel et al., 1997). Our data support a similar conclusion in the STN, given the lack of immunoreactivity of the GluN2C/D antibody in STN tissue from GluN2D−/− mice (Fig. 1). Moreover, we provide evidence that DQP-1105 and CIQ have no significant effect on synaptic transmission in the STN of GluN2D-deficient mice, which further supports the specificity of these modulators and their utility for studying GluN2C/D-containing receptors in native tissues.

The prolonged deactivation time course of NMDAR-EPSCs in the STN is similar to what has been found in other regions proposed to contain synaptic GluN2D (Lozovaya et al., 2004; Brothwell et al., 2008; Harney et al., 2008; Hildebrand et al., 2014; von Engelhardt et al., 2015). This slow deactivation time course could alter the temporal summation of excitatory synaptic inputs into the STN and increase neuronal excitability (Forsythe and Westbrook, 1988; Bourne and Nicoll, 1993; Edmonds et al., 1995). Indeed, longer EPSC deactivation time courses have been linked to stronger synaptic plasticity (Mayer and Miller, 1990; Fox et al., 1991; Carmignoto and Vicini, 1992; Edmonds et al., 1995) and recent studies have suggested a potential role for GluN2D in mediating synaptic plasticity in the hippocampus and striatum (Harney and Anwyl, 2012; Volianskis et al., 2013; Tozzi et al., 2015). GluN2D-containing NMDA receptors may also be expressed at extrasynaptic sites, which could lead to higher tonic NMDA receptor activity in the STN, causing depolarization and increased burst firing (Zhu et al., 2004; Zhu et al., 2005). Several reports have suggested extrasynaptic GluN2D expression in the substantia nigra, hippocampus, and cerebellum (Brickley et al., 2003; Harney et al., 2008; Costa et al., 2009; Wu and Johnson, 2015), but it is unknown whether extrasynaptic NMDA receptors are present in the STN.

Interestingly, many CNS regions that express GluN2D also have a high expression of the GluN2B subunit, including the SNc, SNr, striatum, pallidum, nucleus accumbens, and the dentate gyrus (Monyer et al., 1994; Standaert et al., 1994; Wenzel et al., 1996; Standaert et al., 1999; Brickley et al., 2003). Functional studies have indicated that the GluN2B and GluN2D subunits are concurrently expressed at a subset of synapses in the SNc, striatum, and lamina I neurons of the dorsal horn (Brothwell et al., 2008; Hildebrand et al., 2014). Similarly, the NMDA receptor component of EPSCs in the developing STN was mediated by GluN2B- and GluN2D-containing receptors. The time course of the NMDA receptor component of STN EPSCs is intermediate between the time course of recombinant GluN1-1b/GluN2B and GluN1-1b/GluN2D (Fig. 5B), further suggesting that the NMDA receptors expressed at STN synapses contain the GluN2B and GluN2D subunits. Studies in SNc neurons have suggested that the GluN2D and GluN2B subunits may be expressed as triheteromeric receptors (Jones and Gibb, 2005; Brothwell et al., 2008; Huang and Gibb, 2014). A similar subunit arrangement may be present at synapses in the STN; however, the proportion of triheteromeric receptors containing GluN1/2/2D in the STN is unknown. In addition, the relative expression levels of the GluN1 splice variants remain unclear. The stoichiometry of NMDA receptor subunit composition in STN neurons will be important to understand given the likely impact on the functional and pharmacological properties of NMDA receptors.

An additional finding of our study is that the GluN2D subunit is highly expressed in STN neurons throughout postnatal development and in adulthood. Expression of GluN2D in the adult STN was demonstrated by our biochemical, histological, and in vivo spike-firing experiments (Figs. 1, 2, 7). Recent studies have also demonstrated GluN2D protein expression and synaptic function in the adult rodent striatum (Tozzi et al., 2015; Zhang and Chergui, 2015). Historically, studies have shown a marked decrease in GluN2D expression after 1–2 weeks of age across much of the nervous system (Dunah et al., 1996; Wenzel et al., 1996; Laurie et al., 1997; Lau et al., 2003; Shibata et al., 2003; Liu and Wong-Riley, 2010). An age-dependent decrease in GluN2D-mediated synaptic currents was demonstrated in hippocampal interneurons and SNc neurons (Pearstein et al., 2015; von Engelhardt et al., 2015). Conversely, one study has suggested that GluN2D-containing NMDA receptors are present in adult SNc neurons, but are primarily extrasynaptic (Wu and Johnson, 2015). Further investigations of the developmental changes in GluN2D gene expression and subcellular localization will be important for a better understanding of the role of GluN2D in brain function.

Finally, our study has demonstrated that GluN2D modulators can regulate neuronal firing of STN neurons in vivo. These results suggest that either extrasynaptic receptors are tonically active or that excitatory synaptic drive to the STN activates sufficient NMDA receptors such that modulation affects neuronal excitability and thus spike firing. GluN2D-containing receptors have high glutamate potency (0.5 μM; Erreger et al., 2007), which is compatible with activation by tonic glutamate, estimated in some tissues to reach 3 μM (Edmonds et al., 1995; Timmerman and Westerink, 1997; Rusakov and Kullmann, 1998). In addition, the reduced sensitivity of GluN2D-containing NMDA receptors to Mg2+ inhibition should allow both synaptic and tonic NMDA receptor activation (Monyer et al., 1994; Qian et al., 2005). The role of NMDA receptors in STN firing suggests that targeting the GluN2D subunit could affect the firing rate and perhaps the firing pattern of subthalamic neurons and this could be of therapeutic utility in Parkinson’s disease (Hallett and Standaert, 2004). Notably, in an animal model of Parkinson’s disease, blocking NMDA receptor function in the STN using a pan-NMDA receptor blocker rectified hypokinetic motor symptoms (Pan et al., 2014). Use of nonselective NMDA receptor blockers is not a viable option for treatments given the side effects associated with both competitive antagonists and channel blockers (Nicholson et al., 1997; Nicholson and Balster, 2003; Yuan et al., 2015). However, if inhibition of NMDA receptors by a GluN2D subunit-
selective antagonist shows a limited side effect profile, then these antagonists may be of therapeutic interest.

In conclusion, postsynaptic currents at excitatory synapses in the STN contain both NMDA and AMPA receptor components. The NMDA receptor component of excitatory neurotransmission in the developing STN is mediated primarily by GluN2B- and GluN2D-containing receptors. Importantly, the GluN2D subunit is expressed in the developing and adult STN and modulating GluN2D-containing NMDA receptor function regulates the spike-firing rate in the adult rat STN. Because increased firing rate and altered firing patterns in the STN contribute to the symptoms of Parkinson’s disease (Bergman et al., 1990; DeLong, 1990; Rodriguez et al., 1998; Levy et al., 2000; Obeso et al., 2000), GluN2D-containing NMDA receptors may be a novel therapeutic target for the treatment of this disease.

References


Huang et al., 2000

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003

van der Linden et al., 2003
CrossRef Medline


